Is MTEM or EPRT a better dividend investment in 2026?

MTEM currently yields 2000000.06% with a 5% 5-year dividend growth rate. EPRT yields 3.92% with 5% growth. The better choice depends on your goal: MTEM offers higher current income.

What is the dividend yield difference between MTEM and EPRT?

MTEM has a forward dividend yield of 2000000.06% ($2.00/share annually). EPRT yields 3.92% ($1.21/share annually). The yield gap is 1999996.14 percentage points.

Home › Compare › MTEM vs EPRT

MTEM vs EPRT: Dividend Comparison 2026

MTEM yields 2000000.06% · EPRT yields 3.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MTEM wins by $4.8792278646347776e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

MTEM

● Live price

2000000.06%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.8792278646347776e+39M

Annual income

$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00

Full MTEM calculator →

EPRT

● Live price

3.92%

Share price

$30.77

Annual div

$1.21

5Y div CAGR

29%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$63.4K

Annual income

$12,840.73

Full EPRT calculator →

Portfolio growth — MTEM vs EPRT

📍 MTEM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MTEM	EPRT
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MTEM + EPRT cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MTEM pays

EPRT pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTEM

Annual income on $10K today (after 15% tax)

$170,000,005.10/yr

After 10yr DRIP, annual income (after tax)

$4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/yr

EPRT

Annual income on $10K today (after 15% tax)

$332.87/yr

After 10yr DRIP, annual income (after tax)

$10,914.62/yr

At 15% tax rate, MTEM beats the other by $4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTEM + EPRT for your $10,000?

MTEM: 50%EPRT: 50%

100% EPRT50/50100% MTEM

Portfolio after 10yr

$2.4396139323173888e+39M

Annual income

$2,439,374,001,430,694,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

MTEM

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Altman Z

-24.9

Piotroski

2/9

EPRT

Analyst Ratings

Strong

Buy

Hold

Sell

Consensus: Buy

Price Target

$35.50

+15.4% upside vs current

Range: $33.00 — $37.00

Altman Z

1.8

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTEM buys

EPRT buys

No recent congressional trades found for MTEM or EPRT in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMTEMEPRT

Forward yield	2000000.06% ✓	3.92%
Annual dividend / share	$2.00 ✓	$1.21
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	29% ✓
Portfolio after 10y	$4.8792278646347776e+39M	$63.4K ✓
Annual income after 10y	$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00 ✓	$12,840.73
Total dividends collected	$4.8791964691115763e+39M	$37.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Buy	Buy

Year-by-year: MTEM vs EPRT ($10,000, DRIP)

Year	MTEM Portfolio	MTEM Income/yr	EPRT Portfolio	EPRT Income/yr	Gap
1← crossover	$200,010,706	$200,000,006.00	$11,205	$505.18	+$200.00M → MTEM
2	$3,738,731,992,770	$3,738,517,981,314.42	$12,672	$682.46	+$3738731.98M → MTEM
3	$65,315,068,744,949,500	$65,311,068,301,717,240.00	$14,490	$930.48	+$65315068744.94M → MTEM
4	$1,066,400,958,023,135,400,000	$1,066,331,070,899,578,300,000.00	$16,786	$1,282.69	+$1066400958023135.38M → MTEM
5	$16,272,185,237,131,282,000,000,000	$16,271,044,188,106,197,000,000,000.00	$19,753	$1,791.56	+$16272185237131282432.00M → MTEM
6	$232,054,281,880,765,440,000,000,000,000	$232,036,870,642,561,700,000,000,000,000.00	$23,677	$2,541.64	+$2.3205428188076545e+23M → MTEM
7	$3,092,799,715,549,616,000,000,000,000,000,000	$3,092,551,417,468,003,600,000,000,000,000,000.00	$29,008	$3,672.99	+$3.0927997155496157e+27M → MTEM
8	$38,524,114,942,504,994,000,000,000,000,000,000,000	$38,520,805,646,809,356,000,000,000,000,000,000,000.00	$36,463	$5,425.08	+$3.8524114942504996e+31M → MTEM
9	$448,468,947,092,778,960,000,000,000,000,000,000,000,000	$448,427,726,289,790,500,000,000,000,000,000,000,000,000.00	$47,238	$8,221.57	+$4.4846894709277894e+35M → MTEM
10	$4,879,227,864,634,777,500,000,000,000,000,000,000,000,000,000	$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00	$63,385	$12,840.73	+$4.8792278646347776e+39M → MTEM

MTEM vs EPRT: Complete Analysis 2026

MTEM — Stock

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Full MTEM Calculator →

EPRT — REIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →

📬

Get this MTEM vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTEM vs SCHD MTEM vs JEPI MTEM vs O MTEM vs KO MTEM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.